Pfizer Wins Promotion Contract Row In Pa. Appeals Court

Law360, New York (March 26, 2013, 1:42 PM EDT) -- A Pennsylvania appeals court found Monday that Pfizer Inc. is entitled to an extension in a multiple sclerosis drug promotion agreement it inked with EMD Serono Inc., saying the agreement is valid even though the drug's U.S. Food and Drug Administration approval fell through.

The Pennsylvania Superior Court found that Pfizer's decision to jointly promote EMD Serono's cladribine drug extended the terms of a pre-existing co-promotion agreement between the companies and rejected EMD Serono's argument that the extension applied only if the FDA approved its drug...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.